Morningstar

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class ...

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults The Phase 1 Part 3 trial will enroll a total of 40 obese, otherwise ...
Morningstar

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

NEW ORLEANS, June 5, 2026 /PRNewswire/ -- A new study evaluating the role of acmopatide (CT-868), a once-daily dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonist (GLP-1/GIP ...